Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen.

Kyle A BeauchampKatherine A Johansen TaberDale Muzzey

Published in: Genetics in medicine : official journal of the American College of Medical Genetics (2019)

Based on screened patients predominantly with private coverage, preconception ECS is predicted to reduce the burden of Mendelian disease in a cost-effective manner compared with minimal screening. The data and framework herein may facilitate similar assessments in other cohorts.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
healthcare
prognostic factors
high throughput
health insurance
big data
deep learning
patient reported
affordable care act